À¯¹üÈñ ¸íÀÇ

¼Ä¹°ÇÐÀû Ä¡·á¿Í Á¤½ÅÄ¡·á ¸ðµÎ¸¦ ¾Æ¿ì¸£´Â Á¤½ÅÀÇÇÐ Àü¹®°¡

À¯¹üÈñ ¸íÀÇ

  • ¼Ò ¼Ó
    À¯¹üÈñÁ¤½Å°Ç°­ÀÇÇаú
  • Áø·á°ú
    Á¤½Å°Ç°­ÀÇÇаú
  • Àü¹®ºÐ¾ß
    °øÈ²Àå¾Ö, ¿ì¿ïÀå¾Ö, Á¶¿ïº´, ¼ö¸éÀå¾Ö, Á¤½ÅºÐ¼®Ä¡·á

¼­¿ïÀǴ븦 Á¹¾÷ÇÏ°í ¼­¿ï´ëÇб³º´¿ø¿¡¼­ Àü°øÀÇ ¼ö·Ã ÈÄ Á¤½Å°ú Àü¹®ÀǸ¦ ÃëµæÇÏ¿´°í 1994³âºÎÅÍ 2014³â±îÁö ¼º±Õ°ü´ëÇб³ »ï¼º¼­¿ïº´¿ø¿¡¼­ 20³â°£ Á¤½Å°Ç°­ÀÇÇаú ±³¼ö, °úÀå ¹× ÁÖÀÓ±³¼ö±îÁö ¿ªÀÓÇÏ¿´À½. ¹Ì±¹ University of California, San Diego ´ëÇп¡¼­ 1997³âºÎÅÍ 1999³â±îÁö research fellow·Î ±Ù¹«ÇÏ¿´°í, ¹Ì±¹ San Diego Á¤½ÅºÐ¼®¿¬±¸¼Ò¿¡¼­ Á¤½ÅÄ¡·á Àü¹®°¡ °úÁ¤µµ ÇÔ²² ¼ö·áÇÏ¿´À½. ÁÖ·Î °øÈ²Àå¾Ö, ºÒ¾ÈÀå¾Ö, ¿ì¿ïÁõ, ¼ö¸éÀå¾Ö, Á¤½ÅºÐ¼® ºÐ¾ß¸¦ Àü°øÇÏ¿´°í »ï¼º¼­¿ïº´¿ø ±³¼ö·Î ÀçÁ÷Çϸ鼭 ±¹³»¿Ü À¯¸í ÇмúÁö¿¡ 120Æí ÀÌ»óÀÇ ³í¹®À» ¹ßÇ¥ÇÏ¿´°í ´Ù¼öÀÇ Çмú»óÀ» ¼ö»óÇϱ⵵ ÇÔ. ¶ÇÇÑ Çѱ¹Á¤½ÅºÐ¼®ÇÐȸ ȸÀå, Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ ȸÀå, ´ëÇѼö¸éÀÇÇÐȸ ÀÌ»çÀå, ´ëÇѺҾÈÀÇÇÐȸ °øÈ²-¹üºÒ¾ÈÀå¾Ö ¿¬±¸È¸ ÃÊ´ëȸÀå µîÀ» ¿ªÀÓÇϸ鼭 Ȱ¹ßÇÑ ÇÐȸȰµ¿À» À̾. 2014³âºÎÅÍ Áö±Ý±îÁö À¯¹üÈñ Á¤½Å°Ç°­ÀÇÇаú ¿øÀåÀ¸·Î ±Ù¹«Çϸ鼭 ÀÓ»óÁø·á¿¡ Àü³äÇϰí ÀÖÀ½

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • ¼­¿ï´ëÇб³ Àǰú´ëÇÐ Çлç
  • ¼­¿ï´ëÇб³ Àǰú´ëÇÐ ¼®»ç
  • ¼­¿ï´ëÇб³ Àǰú´ëÇÐ ¹Ú»ç

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) À¯¹üÈñÁ¤½Å°Ç°­ÀÇÇаú ¿øÀå
  • ¼º±Õ°ü´ëÇб³ Àǰú´ëÇÐ »ï¼º¼­¿ïº´¿ø Á¤½Å°Ç°­ÀÇÇаú °úÀå ¹× ÁÖÀÓ±³¼ö

¼ö»ó³»¿ª

Awards List
  • ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ GSK Çмú»ó
  • ´ëÇѺҾÈÀÇÇÐȸ º¸·ÉÇмú»ó
  • Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ Çмú»ó
  • ´ëÇѼö¸éÀÇÇÐȸ Çмú»ó
  • °úÇбâ¼úÃÑ¿¬ÇÕȸ Çмú»ó

ÇÐȸȰµ¿

Academic activities
  • 2009 ~ 2011´ëÇѼö¸éÀÇÇÐȸ ÀÌ»çÀå
  • 2011 ~ 2013Çѱ¹Á¤½ÅºÐ¼®ÇÐȸ ȸÀå
  • 2014 ~ 2016Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ ȸÀå
  • 2011 ~ 2014´ëÇѺҾÈÀÇÇÐȸ °øÈ², ¹üºÒ¾ÈÀå¾Ö ¿¬±¸È¸Àå
´Ù½Ã ÇÁ·ÎÀÌÆ®; ³» ¸¶À½ÀÇ »óó¸¦ ÀдÙ.
´ëÇ¥¼­Àû

´Ù½Ã ÇÁ·ÎÀÌÆ®; ³» ¸¶À½ÀÇ »óó¸¦ ÀдÙ.

  • ÀúÀÚ(±Û)À¯¹üÈñ
  • ÃâÆÇ»ç´õ½£ ÃâÆÇ»ç
  • ¹ßÇàÀÏ2016³â 6¿ù 30ÀÏ
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 4°Ç
Á¦ ¸ñ ±×¸²ÀÚ ¾ÆÀ̰¡ ¿ï°í ÀÖ´Ù.
ÃâÆÇ»ç »ý°¢ ¼ÓÀÇ Áý ¹ßÇàÀÏ 2018³â
Á¦ ¸ñ ºÒ¾ÈÀå¾Ö ¡¤ ½Å°æÁ¤½ÅÀÇÇÐ 2ÆÇ
ÃâÆÇ»ç Áß¾Ó¹®È­»ç ¹ßÇàÀÏ 2005³â
Á¦ ¸ñ Psychiatric and Psychosocial Complications in Chronic Dialysis. In : Complications of Dialysis. edited by Mehta R and Ramiere N.
ÃâÆÇ»ç New York, Marcel Dekker, Inc. ¹ßÇàÀÏ 2000³â
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ Changes in cerebral cortex and limbic brain functions after short-term paroxetine treatment in panic disorder: An [18F]FDG-PET pilot study.
¹ßÇ¥³âµµ 2010³â ¹ßÇ¥Áö Psychiatry Investigation
Á¦ ¸ñ Sympathetic nervous function and the effect of the catechol-O-methyltransferase Val158Met polymorphism in patients with panic disorder.
¹ßÇ¥³âµµ 2010³â ¹ßÇ¥Áö J of Affective Disorder
Á¦ ¸ñ Platelet serotonin transporter function after short-term paroxetine treatment in patients with panic disorder.
¹ßÇ¥³âµµ 2010³â ¹ßÇ¥Áö Psyciatry Research
Á¦ ¸ñ Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: A randomized, open-labeled trial.
¹ßÇ¥³âµµ 2009³â ¹ßÇ¥Áö Psyciatry Research
Á¦ ¸ñ ¥â-adrenoceptor affinity as a biological predictor of treatment response to paroxetine in patients with acute panic disorder.
¹ßÇ¥³âµµ 2008³â ¹ßÇ¥Áö J of Affective Disorder
Á¦ ¸ñ Mood states, sympathetic activity and in vivo ¥â-adrenergic receptor function in a normal population.
¹ßÇ¥³âµµ 2008³â ¹ßÇ¥Áö Depression & Anxiety
Á¦ ¸ñ Increased cholesterol levels after paroxetine treatment in patients with panic disorder
¹ßÇ¥³âµµ 2005³â ¹ßÇ¥Áö J Clin Psychopharmacol

¸íÀÇqna ¸íÀÇ QnA

Q °¡Àå °ü½É ÀÖ´Â ºÐ¾ß¿Í ¾÷ÀûÀÌ ÀÖ´Ù¸é ¾Ë·ÁÁÖ¼¼¿ä

°øÈ²Àå¾Ö¿¡ ´ëÇÑ »ý¹°ÇÐÀû ¿¬±¸¿¡ °¡Àå Å« °ü½ÉÀ» µÎ¾î¿Ô°í 2002³âµµ¿¡ Á¤½ÅÀÇÇÐ ºÐ¾ß¿¡¼­ ¼¼°èÀûÀÎ ÇмúÁö·Î ÀÎÁ¤¹Þ´Â American Journal of Psychiatry¿¡ Catechol-O-methyltransferase genetic polymorphism in panic disorder¶ó´Â ³í¹®À» ¹ßÇ¥ÇÏ¿© °øÈ²Àå¾Ö¿¡¼­ À¯ÀüÀû ¹ßº´ ¿äÀο¡ ´ëÇÑ ÁÖ¿ä °¡¼³À» óÀ½À¸·Î ¹ßÇ¥ÇÏ¿´½À´Ï´Ù. ±×¸®°í ÀÌ ³í¹®À¸·Î 2004³âµµ¿¡ ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ GSK Çмú»ó°ú Çѱ¹°úÇбâ¼úÃÑ¿¬ÇÕȸ¿¡¼­ ¿ì¼ö¿¬±¸ÀÚ¿¡°Ô ¼ö¿©ÇÏ´Â Çмú»óÀ» ¼ö»óÇϱ⵵ ÇÏ¿´½À´Ï´Ù.

Q ȯÀÚ Áø·á¿¡ ÀÖ¾î °¡Àå Áß¿äÇÏ°Ô »ý°¢ÇÏ´Â °¡Ä¡´Â?

ȯÀÚ°¡ ÀÚÄ© ³¸¼³°í ±äÀåÇÒ ¼öµµ ÀÖ´Â Á¤½Å°ú Áø·á¿¡ °¡´ÉÇÑ Æí¾ÈÇÏ°Ô ÀûÀÀÇÒ ¼ö ÀÖµµ·Ï µ½°í µû¶ó¼­ ȯÀÚÀÇ ¾ê±â¸¦ ÃÖ´ëÇÑ °æÃ»ÇÏ·Á°í ³ë·ÂÇÕ´Ï´Ù. ±×¸®°í ¾à¹°Ä¡·á »Ó ¾Æ´Ï¶ó Á¤½ÅºÐ¼®Ä¡·á °°Àº È¿°úÀûÀÎ ½É¸®Ä¡·á¸¦ º´ÇàÇÏ¿© °¡´ÉÇÑ ºü¸¥ ½Ã°£³»¿¡ ȯÀÚÀÇ Ä¡·á¸¦ ¼º°øÀûÀ¸·Î Á¾°áÇÒ ¼ö ÀÖµµ·Ï ³ë·ÂÇÏ´Â ÆíÀÔ´Ï´Ù.

Q ȯÀڵ鿡°Ô ÀüÇÏ°í ½ÍÀº ¸»¾¸

Á¤½ÅÁúȯ ¿ª½Ã ´Ù¸¥ ÀÇÇÐÀû Áúº´µéó·³ ¿À·¡ ¹æÄ¡µÉ¼ö·Ï ¾ÇÈ­µÇ¾î Àå±âÀûÀÎ ¿¹Èİ¡ ¾ÈÁÁ¾ÆÁö´Â °æ¿ì°¡ ´Ù¹Ý»çÀÔ´Ï´Ù. µû¶ó¼­ Á¤½ÅÀûÀÎ ¹®Á¦°¡ ÀÖ´Ù°í ÀÎÁöÇÏ°Ô µÇ¸é °¡´ÉÇÑ »¡¸® °¡³¢¿î Á¤½Å°Ç°­ÀÇÇаú Ŭ¸®´ÐÀ» ¹æ¹®ÇÏ¿© Áø·á¸¦ º¸°í Á¤È®ÇÑ Áø´Ü°ú Ä¡·á¸¦ ¹Ù·Î ½ÃÀÛÇϱ⸦ ±ÇÀ¯µå¸³´Ï´Ù.

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

À¯¹üÈñÁ¤½Å°Ç°­ÀÇÇаú

ÀÇ¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
02-578-2014
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

À¯¹üÈñ Á¤½Å°Ç°­ÀÇÇаú´Â 2014³â¿¡ °³¿øÇÏ¿´°í 3È£¼± µµ°î¿ª ±Ùó¿¡ À§Ä¡Çϰí ÀÖ½À´Ï´Ù. Á¤½Å°ú Àü¹®ÀÇÀÎ À¯¹üÈñ ¿øÀåÀ» Æ÷ÇÔÇÏ¿© ÀÓ»ó½É¸®Àü¹®°¡ 2Àΰú °£È£»ç 2¸íÀÌ ÇÔ²² ±Ù¹«Çϰí ÀÖ½À´Ï´Ù. ÁÖ·Î ºÒ¾ÈÀå¾Ö, °øÈ²Àå¾Ö, ¿ì¿ïÁõ, Á¶¿ïÁõ, ¼ö¸éÀå¾Ö, ¼ºÀÎ ADHD ȯÀÚµéÀ» Áø·áÇϰí ÀÖÀ¸¸ç ¾à¹°Ä¡·á »Ó ¾Æ´Ï¶ó °¢Á¾ ½É¸®Ä¡·á, Á¤½ÅºÐ¼®Ä¡·áµµ ÇÔ²² ½ÃÇàÇϰí ÀÖ½À´Ï´Ù.

À¯¹üÈñÁ¤½Å°Ç°­ÀÇÇаú		 À̹ÌÁö

¼­¿ïƯº°½Ã °­³²±¸ ¾ðÁÖ·Î 30±æ 21 ¾ÆÄ«µ¥¹Ì½ºÀ§Æ® Aµ¿ 202-3È£

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä